Cheryl Williams, MD
Allergy & Immunology · New Orleans, LANPI 1366493785
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,751 of the $12,115 with a category attached, or 64.0%. 22 manufacturers reported payments, led by Genentech USA, Inc. at 34.9% of the total. Reporting peaked in 2023 at $5,709 and has fallen 92.7% since, to $418 in 2025.
Across 322 payments — averaging $37.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$4K
- GSK$3K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$619
- Sanofi$296
- Viiv Healthcare Company$213
- plus $985 from 16 others
Across 8 payments — averaging $1891.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$15K
What the payments were for
- Consulting fees$3,64530%
- Travel & lodging$5865%
- Food & beverage$7,75164%
- Education$1331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 3 | $4,231 |
| GSK | 134 | $3,372 |
| AstraZeneca | 113 | $2,399 |
| Regeneron Healthcare Solutions, Inc. | 20 | $619 |
| Sanofi | 11 | $296 |
| Viiv Healthcare Company | 2 | $213 |
| Amgen | 6 | $153 |
| Boehringer Ingelheim | 4 | $153 |
| Novartis | 6 | $122 |
| Gilead | 1 | $102 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Mylan Specialty L.p. | 3 | $57 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Hikma Pharmaceuticals USA | 2 | $45 |
| Aytu Biopharma, Inc. | 2 | $45 |
| Greer Laboratories, Inc. | 2 | $32 |
| Pfizer | 2 | $30 |
| Verona Pharma, Inc. | 1 | $27 |
| Dermavant Sciences, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| USWM, LLC | 1 | $26 |
| Kaleo, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,115 in reported general payments places this provider in the 85th percentile of 62 allergy & immunology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 14 | $60,176 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $51,602 |
| NucalaMepolizumab | 12 | $51,363 |
| Dupixent SyringeDupilumab | 11 | $48,423 |
| XolairOmalizumab | 14 | $38,303 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $12,880 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,261 |
| Azelastine Hcl | 105 | $3,767 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $2,445 |
| Fluticasone Propionate | 111 | $2,361 |
| Epinephrine | 13 | $2,260 |
| Ventolin HfaAlbuterol Sulfate | 16 | $817 |
| Levocetirizine Dihydrochloride | 111 | $809 |
| Montelukast Sodium | 98 | $577 |
| Ipratropium Bromide | 23 | $347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $3,372 | $107,22582 claims |
| AstraZenecaTezspire, Symbicort | $2,399 | $73,05764 claims |
| Hikma Pharmaceuticals USAEpinephrine | $45 | $2,26013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 62 allergy & immunology providers in Louisiana.
Other allergy & immunology in New Orleans
- Reena MehtaNew Orleans$159K
- Kenneth ParisNew Orleans$150K
- Luke WallNew Orleans$7K
- Stephen DerbesNew Orleans$2K
- Michelle Korah-SedgwickNew Orleans$2K
- Jamie LurieNew Orleans$2K
- William DavisNew Orleans$2K
- Elizabeth WisnerNew Orleans$2K
- Dexter MatranaNew Orleans$1K
- Meaghan McMahonNew Orleans$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.